Related Research Articles
Gefitinib,sold under the brand name Iressa,is a medication used for certain breast,lung and other cancers. Gefitinib is an EGFR inhibitor,like erlotinib,which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore,it is only effective in cancers with mutated and overactive EGFR,but resistances to gefitinib can arise through other mutations. It is marketed by AstraZeneca and Teva.
Massachusetts General Hospital is a teaching hospital located in the West End neighborhood of Boston,Massachusetts. It is the original and largest clinical education and research facility of Harvard Medical School/Harvard University,and houses the world's largest hospital-based research program with an annual research budget of more than $1.2 billion in 2021. It is the third-oldest general hospital in the United States with a patient capacity of 999 beds. Along with Brigham and Women's Hospital,Mass General is a founding member of Mass General Brigham,formerly known as Partners HealthCare,the largest healthcare provider in Massachusetts.
Erlotinib,sold under the brand name Tarceva among others,is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) —either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation —which has spread to other parts of the body. It is taken by mouth.
Dana–Farber Cancer Institute (DFCI) is a comprehensive cancer treatment and research center in Boston,Massachusetts. Dana-Farber is the founding member of the Dana-Farber/Harvard Cancer Center,Harvard's Comprehensive Cancer Center designated by the National Cancer Institute,and one of the 15 clinical affiliates and research institutes of Harvard Medical School.
Non-small-cell lung cancer (NSCLC),or non-small-cell lung carcinoma,is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class,NSCLCs are relatively insensitive to chemotherapy,compared to small-cell carcinoma. When possible,they are primarily treated by surgical resection with curative intent,although chemotherapy has been used increasingly both preoperatively and postoperatively.
The Addario Lung Cancer Medical Institute (ALCMI) is a 501c(3) nonprofit organization dedicated to forwarding lung cancer research that can lead to new therapeutics,diagnostics,and a better understanding of lung cancer risk factors in families and in younger people,and resistance mechanisms. Made up of an international consortium of 25 of the world's premier oncology research institutions,ALCMI partners with the top minds from the most respected medical facilities,providing financial support and access to a team of experts and staff to assist in launching and managing investigator-initiated clinical trials.
Osimertinib,sold under the brand name Tagrisso,is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016,Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.
Nathanael S. Gray is an American chemist. He serves as Krishnan-Shah Family Professor of chemical and systems biology at Stanford University and director of cancer therapeutics programme at Stanford University School of Medicine. Previously he was a Nancy Lurie Marks Professor of biological chemistry and molecular pharmacology at Harvard Medical School and professor of cancer biology at Dana–Farber Cancer Institute. Gray is also co-founder,science advisory board member (SAB) and equity holder in C4 Therapeutics,Gatekeeper,Syros,Petra,B2S,Aduro,Jengu,Allorion,Inception Therapeutics,and Soltego. C4 Therapeutics,which offered IPO in 2020,was founded based on the research of Jay Bradner,current president of Novartis Institutes for BioMedical Research (NIBR),and of Nathanael S. Gray,while he was professor at Harvard Medical School. Before moving to Stanford University,Nathanael S. Gray created Center for Protein Degradation at Harvard Medical School with $80 million agreement with Deerfield Management venture capital firm. In 2020,Gray Lab permanently moved to Stanford University,that was stated by Stuart Schreiber,co-founder of Broad Institute as "Stanford's huge gain".
Amit Dutt is an Indian scientist,geneticist and the principal investigator at Advanced Centre for Treatment,Research and Education in Cancer (ACTREC) of Tata Memorial Centre. Known for his studies on Fibroblast growth factor receptor,Dutt is a Wellcome Trust / DBT India Alliance Intermediate Fellow. The Council of Scientific and Industrial Research,the apex agency of the Government of India for scientific research,awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology,one of the highest Indian science awards,for his contributions to medical sciences in 2017.
Catherine J. Wu is an American physician-scientist who studies oncology. She is a Professor of Medicine and Chief of Division of Stem Cell Transplantation and Cellular Therapies at the Dana–Farber Cancer Institute. Her research focuses on longitudinal studies of patients with chronic lymphocytic leukemia (CLL).
Mobocertinib,sold under the brand name Exkivity,is used for the treatment of non-small cell lung cancer.
Amivantamab,sold under the brand name Rybrevant,is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and mesenchymal–epithelial transition (MET) receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations:epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Scott Allen Armstrong is an American pediatric oncologist and cancer biologist focused on chromatin-based control of gene expression in cancer and therapeutic discovery. Armstrong and his team were the first to isolate rare leukemia stem cells in a mouse model of leukemia.
Levi A. Garraway is an American oncologist. His research team was among the first to adapt genomics technologies to enable scalable,high-throughput clinical approaches to cancer gene mutation profiling. As a result,he was inducted into the American Society for Clinical Investigation,American Association for Cancer Research,and National Academy of Medicine.
Margaret Ann Shipp is an American hematologic oncologist. She is the Douglas S. Miller Chair in Hodgkin Lymphoma at Harvard Medical School. Shipp is an elected Fellow of the American Society for Clinical Investigation and National Academy of Medicine.
Benjamin Levine Ebert is the Chair of Medical Oncology at the Dana–Farber Cancer Institute and the George P. Canellos,MD and Jean S. Canellos Professor of Medicine at Harvard Medical School. Ebert has been the president and CEO of Dana-Farber since October 2024,succeeding Laurie Glimcher.
Nancy Lin is an American oncologist who works at the Dana-Farber Cancer Institute and is an Associate Professor of Medicine at Harvard Medical School. Her research considers new diagnostic strategies and treatment pathways for HER2 positive breast cancer.
Personalized genomics is the human genetics-derived study of analyzing and interpreting individualized genetic information by genome sequencing to identify genetic variations compared to the library of known sequences. International genetics communities have spared no effort from the past and have gradually cooperated to prosecute research projects to determine DNA sequences of the human genome using DNA sequencing techniques. The methods that are the most commonly used are whole exome sequencing and whole genome sequencing. Both approaches are used to identify genetic variations. Genome sequencing became more cost-effective over time,and made it applicable in the medical field,allowing scientists to understand which genes are attributed to specific diseases.
Aumolertinib is a pharmaceutical drug for the treatment of cancer. It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
References
- ↑ "Endowed Chairs - Dana-Farber Cancer Institute | Boston, MA". www.dana-farber.org. Retrieved 2022-05-18.
- ↑ "Center for Cancer Genomics Team - Dana-Farber Cancer Institute | Boston, MA". www.dana-farber.org. Retrieved 2022-05-18.
- ↑ "Matthew Meyerson". Broad Institute. 2015-06-29. Retrieved 2022-05-18.
- ↑ "Meyerson, Matthew L., 1963-". Library of Congress. Retrieved January 2, 2022.
- 1 2 Krenkel, Karen A. (2006). "Oral history interview with Matthew L. Meyerson". Science History Institute. Retrieved January 2, 2022.
- ↑ Printz, Carrie (April 9, 2021). "First person profile: Matthew L. Meyerson, MD, PhD". Cancer . 127 (7): 991–993. doi:10.1002/cncr.33520. PMID 33836106. S2CID 233194918 . Retrieved January 2, 2022.
- ↑ Bridger, Haley (January 18, 2011). "Five Questions for Matthew Meyerson". Broad Institute. Retrieved January 2, 2022.
- 1 2 "Matthew L. Meyerson, MD, PhD". Dana–Farber Cancer Institute. Retrieved January 2, 2022.
- 1 2 Fallik, Dawn (November 21, 2021). "Cracking the Cancer Code Requires Both Quiet and Chaos". Onclive. Retrieved January 2, 2022.
- ↑ "Genetic computation tells man from microbe". Harvard Gazette. February 8, 2002. Retrieved January 2, 2022.
- ↑ "Study identifies which patients can benefit from targeted lung cancer drug –– and why". Eurekalert. April 29, 2004. Retrieved January 2, 2022.
- ↑ Adrienne Burke (February 21, 2012). "Foundation Medicine: Personalizing Cancer Drugs". MIT Technology Review. Retrieved January 2, 2022.
- ↑ Allan Maurer (September 28, 2017). "Foundation Medicine building RTP lab into key hub". WRAL TechWire. Retrieved January 2, 2022.
- ↑ "Our Research Impact: 2009 Prize Winners | Memorial Sloan Kettering Cancer Center". www.mskcc.org. Retrieved 2022-04-26.
- ↑ "Two new studies link bacteria to colon cancer". CTV News. October 18, 2011. Retrieved January 2, 2022.
- ↑ Higgins, Laurie (October 27, 2014). "LUNGevity: Funding research for a cure". Cape Code Times. Retrieved January 2, 2022.
- ↑ "One of world's leading scientists, Dr. Matthew L. Meyerson, to receive Han-Mo Koo Memorial Award". Eurekalert. April 14, 2016. Retrieved January 2, 2022.
- ↑ "8 HMS Faculty Elected to National Academy of Medicine". Harvard University. October 16, 2018. Retrieved January 2, 2022.
- ↑ Nomburg, Jason; Meyerson, Matthew; DeCaprio, James A. (December 1, 2020). "Pervasive generation of non-canonical subgenomic RNAs by SARS-CoV-2". Genome Medicine . 12 (108): 108. doi: 10.1186/s13073-020-00802-w . PMC 7704119 . PMID 33256807.
- ↑ "Two Dana-Farber faculty members elected as Fellows of the American Association for the Advancement of Science". Dana–Farber Cancer Institute. November 24, 2020. Retrieved January 2, 2022.
- ↑ "Giants of Cancer Care® Announces Ninth Annual Class of Inductees". PR Newswire. September 16, 2021. Retrieved January 2, 2022.
- ↑ "Marriage of Hoenlg / Meyerson". The Boston Globe. February 28, 1988. Retrieved January 2, 2022– via newspapers.com.
| International | |
|---|---|
| National | |
| Academics | |
